| Schedule of Accrued Liabilities |
Accrued liabilities consisted of the following (in thousands): | | | | | | | | | | | | | December 31, | | 2025 | | 2024 | | Rebates and other sales deductions | $ | 459,837 | | | $ | 342,717 | | | Employee compensation and benefits | 215,351 | | | 153,133 | | | Accrued royalties | 47,075 | | | 36,802 | | | Clinical trial accruals | 41,967 | | | 49,962 | | | Accrued interest | 40,667 | | | 41,626 | | | Inventory-related accruals | 34,046 | | | 25,509 | | | Sales return reserve | 26,412 | | | 26,428 | | | Accrued development expenses | 24,371 | | | 23,099 | | | Consulting and professional services | 22,977 | | | 26,221 | | | Selling and marketing accruals | 15,405 | | | 26,981 | | | Current portion of lease liabilities | 14,717 | | | 14,779 | | | Accrued construction-in-progress | 14,308 | | | 10,061 | | | Derivative instrument liabilities | 4,225 | | | 10,198 | | | Accrued collaboration expenses | 1,117 | | | 18,005 | | | Accrued milestones | — | | | 27,500 | | | | | | | | | | | | | | | Other | 71,695 | | | 77,926 | | | Total accrued liabilities | $ | 1,034,170 | | | $ | 910,947 | |
|